VDN | Vaccine Pipeline
Biopharmaceutical Portfolio Directory

Vaccine Developers & Sponsors

Explore research and clinical trial portfolios across 67 vaccine manufacturers and biopharma sponsors worldwide.

49 Candidates 22 Targets

GSK

Approved / Licensed: 2, Phase 3 Clinical Trial: 10, Discontinued / Inactive: 24

54 Linked Trials Portfolio →
27 Candidates 14 Targets

Sanofi

Phase 3 Clinical Trial: 6, Discontinued / Inactive: 12, Phase 2 Clinical Trial: 6

33 Linked Trials Portfolio →
25 Candidates 16 Targets

Merck

Phase 3 Clinical Trial: 3, Discontinued / Inactive: 15, Phase 2 Clinical Trial: 1

30 Linked Trials Portfolio →
22 Candidates 13 Targets

Sinovac

Phase 3 Clinical Trial: 13, Discontinued / Inactive: 5, Phase 2 Clinical Trial: 2

27 Linked Trials Portfolio →
18 Candidates 12 Targets

Moderna

Regulatory Submission Filed: 2, Approved / Licensed: 4, Phase 3 Clinical Trial: 5

18 Linked Trials Portfolio →
18 Candidates 12 Targets

Pfizer

Phase 3 Clinical Trial: 4, Approved / Licensed: 1, Discontinued / Inactive: 9

22 Linked Trials Portfolio →
11 Candidates 7 Targets

CanSino Biologics

Phase 3 Clinical Trial: 5, Discontinued / Inactive: 2, Phase 2 Clinical Trial: 2

17 Linked Trials Portfolio →
10 Candidates 8 Targets

BioNTech

Phase 3 Clinical Trial: 4, Phase 2 Clinical Trial: 2, Phase 1 Clinical Trial: 3

11 Linked Trials Portfolio →
7 Candidates 3 Targets

Novavax

Phase 3 Clinical Trial: 2, Approved / Licensed: 1, Discontinued / Inactive: 4

5 Linked Trials Portfolio →
5 Candidates 3 Targets

Valneva

Approved / Licensed: 3, Discontinued / Inactive: 2

5 Linked Trials Portfolio →
5 Candidates 4 Targets

Serum Institute of India

Discontinued / Inactive: 1, Phase 3 Clinical Trial: 2, Phase 2 Clinical Trial: 1

5 Linked Trials Portfolio →
5 Candidates 4 Targets

Bavarian Nordic

Phase 3 Clinical Trial: 1, Discontinued / Inactive: 2, Phase 2 Clinical Trial: 2

5 Linked Trials Portfolio →
4 Candidates 3 Targets

Vaxcyte

Phase 3 Clinical Trial: 2, Phase 2 Clinical Trial: 1, Phase 1 Clinical Trial: 1

5 Linked Trials Portfolio →
4 Candidates 4 Targets

Emergent BioSolutions

Approved / Licensed: 1, Discontinued / Inactive: 3

3 Linked Trials Portfolio →
4 Candidates 4 Targets

AstraZeneca

Discontinued / Inactive: 1, Phase 3 Clinical Trial: 1, Phase 2 Clinical Trial: 1

5 Linked Trials Portfolio →
4 Candidates 3 Targets

Takeda

Phase 3 Clinical Trial: 2, Discontinued / Inactive: 2

5 Linked Trials Portfolio →
4 Candidates 4 Targets

CureVac

Discontinued / Inactive: 4

6 Linked Trials Portfolio →
4 Candidates 3 Targets

Janssen (Johnson & Johnson)

Discontinued / Inactive: 4

4 Linked Trials Portfolio →
4 Candidates 4 Targets

Dynavax

Phase 2 Clinical Trial: 2, Discontinued / Inactive: 2

4 Linked Trials Portfolio →
3 Candidates 3 Targets

Emory University

Phase 3 Clinical Trial: 3

4 Linked Trials Portfolio →
3 Candidates 3 Targets

Novartis Pharmaceuticals

Discontinued / Inactive: 1, Phase 3 Clinical Trial: 1, Phase 2 Clinical Trial: 1

3 Linked Trials Portfolio →
3 Candidates 3 Targets

Bharat Biotech

Phase 3 Clinical Trial: 1, Phase 2 Clinical Trial: 1, Discontinued / Inactive: 1

3 Linked Trials Portfolio →
2 Candidates 2 Targets

Pfizer-BioNTech

Phase 3 Clinical Trial: 1, Approved / Licensed: 1

0 Linked Trials Portfolio →
2 Candidates 2 Targets

Tor Biering-Sørensen

Phase 3 Clinical Trial: 2

2 Linked Trials Portfolio →
2 Candidates 2 Targets

Bandim Health Project

Discontinued / Inactive: 1, Phase 3 Clinical Trial: 1

3 Linked Trials Portfolio →
2 Candidates 1 Target

Murdoch Childrens Research Institute

Phase 3 Clinical Trial: 1, Discontinued / Inactive: 1

2 Linked Trials Portfolio →
2 Candidates 2 Targets

University of Sao Paulo General Hospital

Phase 3 Clinical Trial: 2

3 Linked Trials Portfolio →
2 Candidates 2 Targets

Canadian Immunization Research Network

Phase 3 Clinical Trial: 2

2 Linked Trials Portfolio →
1 Candidate 1 Target

MCM Vaccine Company

Approved / Licensed: 1

0 Linked Trials Portfolio →
1 Candidate 1 Target

Aarhus University Hospital

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Well- Konnect Healthcare Services and Research Firm

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Chinese University of Hong Kong

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Partha Basu

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

University Health Network, Toronto

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Walvax Biotechnology Co.

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Monash University

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Sunnybrook Health Sciences Centre

Discontinued / Inactive: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Instituto de Investigación Marqués de Valdecilla

Discontinued / Inactive: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Mark Stegall

Discontinued / Inactive: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Singapore General Hospital

Phase 2 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Central Adelaide Local Health Network Incorporated

Phase 2 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

University of Florida

Phase 2 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

National Institute of Allergy and Infectious Diseases (NIAID)

Discontinued / Inactive: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Instituto Nacional de Salud Publica, Mexi

Discontinued / Inactive: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Novartis

Discontinued / Inactive: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Phase 1 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Wroclaw Medical University

Phase 3 Clinical Trial: 1

2 Linked Trials Portfolio →
1 Candidate 1 Target

University of Washington

Phase 3 Clinical Trial: 1

2 Linked Trials Portfolio →
1 Candidate 1 Target

National Cancer Institute (NCI)

Phase 3 Clinical Trial: 1

2 Linked Trials Portfolio →
1 Candidate 1 Target

Mahidol University

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Louisiana State University Health Sciences Center in New Orleans

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Poitiers University Hospital

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Miquel Angel Pavon Ribas

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Laure Pittet, MD-PhD

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

University of North Carolina, Chapel Hill

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Xiamen Innovax Biotech Co.

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

University of British Columbia

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

University Ghent

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Centre Hospitalier Universitaire de Saint Etienne

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Mercy Medical Center

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Women and Infants Hospital of Rhode Island

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

University of Oxford

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Washington University School of Medicine

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Oswaldo Cruz Foundation

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

The University of Texas Medical Branch, Galveston

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

University of Pennsylvania

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →
1 Candidate 1 Target

Miriam Elfström

Phase 3 Clinical Trial: 1

1 Linked Trial Portfolio →